This site is intended for Healthcare professionals only.
Elsevier-Clinicalkey

Alembic Pharma gets USFDA nod for depressive disorder drug


Alembic Pharma gets USFDA nod for depressive disorder drug

Alembic Pharma has recently received approval from USFDA  to market its product which is a generic equivalent of Wyeth Pharma Inc’s Pristiq tablets.

New Delhi: Alembic Pharma said it has received approval from the US health regulator to market Desvenlafaxine extended-release tablets, used to treat a major depressive disorder. The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Wyeth Pharma Inc’s Pristiq tablets, Alembic Pharmaceuticals said in a regulatory filing.

According to IQVIA, Desvenlafaxine extended-release tablets has a market size of around USD 13.3 million for twelve months ending December 2017.

Read Also: Alembic Pharma gets USFDA nod for an anti-depression drug

 



Source: PTI
0 comment(s) on Alembic Pharma gets USFDA nod for depressive disorder drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted